cytotoxic drug-induced neutropenia and the common need to replace aplastic bone marrow with transplanted haematopoietic cells. Treating chemotherapy-induced neutropenia. The most common ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment ... related to rituximab-induced B lymphopenia.

Mathematical modelling, data science and biostatistics specialist Physiomics announced on Wednesday that its Innovate ...